Treatment of diseases caused by viral infection

A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, comprising administering to said mammal a composition comprising ribavirin or a derivative thereof effective against the Ljungan virus, said mammal receiving pleconaril or a derivative thereof effective against the Ljungan virus, and said administering step occurring simultaneously or sequentially with the receiving pleconaril or a derivative thereof.

A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, comprising administering to said mammal a composition comprising pleconaril or a derivative thereof effective against the Ljungan virus, said mammal receiving ribavirin or a derivative thereof effective against the Ljungan virus, and said administering step occurring simultaneously or sequentially with the receiving ribavirin or a derivative thereof.

A composition comprising ribavirin or a derivative thereof effective against a Ljungan virus and pleconaril or a derivative thereof effective against a Ljungan virus.

A kit comprising a first pharmaceutical composition comprising ribavirin or a derivative thereof effective against a Ljungan virus and a second pharmaceutical composition comprising pleconaril or a derivative thereof effective against a Ljungan virus, the first and second pharmaceutical compositions being suitable for simultaneous or sequential administration for the treatment of a disease that is caused by a Ljungan virus infection.

A method of making a medicament for treatment of a disease in a mammal that is caused by a Ljungan virus infection by combining ribavirin or a derivative thereof effective against a Ljungan virus and pleconaril or a derivative thereof effective against a Ljungan virus into a medicament.

A method of prophylactic and/or therapeutic treatment of a mammal for a disease that is caused by a Ljungan virus infection, comprising administering to said mammal of an antivirally effective amount of ribavirin or a derivative thereof effective against the Ljungan virus, eliminating or inhibiting proliferation of said virus in said mammal and at the same time preventing and/or treating said disease in said mammal.

A composition comprising:

• a) ribavirin or a derivative thereof effective against a Ljungan virus;
• and b) one or more agents selected from the group consisting of an anti-Ljungan virus antibody and an interferon.

A kit comprising a first pharmaceutical composition comprising ribavirin or a derivative thereof effective against a Ljungan virus and a second pharmaceutical composition comprising an anti-Ljungan virus antibody, the first and second pharmaceutical compositions being suitable for simultaneous or sequential administration for the treatment of a disease that is caused by a Ljungan virus infection.

A kit comprising a first pharmaceutical composition comprising ribavirin or a derivative thereof effective against a Ljungan virus and a second pharmaceutical composition comprising an interferon, the first and second pharmaceutical compositions being suitable for simultaneous or sequential administration for the treatment of a disease that is caused by a Ljungan virus infection.

A kit comprising a first pharmaceutical composition comprising ribavirin or a derivative thereof effective against a Ljungan virus, a second pharmaceutical composition comprising an interferon, and a third pharmaceutical composition comprising an anti-Ljungan virus antibody, the first, second and third pharmaceutical compositions being suitable for simultaneous or sequential administration for the treatment of a disease that is caused by a Ljungan virus infection.